<DOC>
	<DOCNO>NCT01079988</DOCNO>
	<brief_summary>This pilot investigational study appropriate therapeutic regimen treat subject experience inflammatory recurrence ( rebound ) psoriatic disease upon discontinuation efalizumab therapy biological mechanism involve inflammatory disease recurrence control .</brief_summary>
	<brief_title>Study Therapeutic Options Subjects Discontinuing Efalizumab Experiencing Disease Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Participation Genentech study ACD2601g , Genentech study HUPA 600 Serono study IMP24011 . Inflammatory psoriasis disease recurrence occur 2 month discontinuation efalizumab require immediate therapeutic control opinion Investigator . Psoriasis rapidly develop , symptomatic inflammatory nature . Written informed consent , give prior studyrelated procedure part subject 's normal medical care , understand subject could withdraw consent time without prejudice future medical care . Female subject neither pregnant breastfeeding , lack childbearing potential , define either : Being postmenopausal surgically sterile , Using accept form contraception . Confirmation subject pregnant establish negative urinary hCG test SD1 . A pregnancy test require subject postmenopausal surgically sterile . Outpatient status time enrolment . Disease recurrence part natural disease progression , inflammatory nature , relate efalizumab study medication previous study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Discontinuation efalizumab</keyword>
	<keyword>Managing inflammatory recurrence</keyword>
</DOC>